Estradiol Levels and Clinical Considerations in Males

Clinical Thresholds and Management

In males not on gender-affirming hormone therapy, estradiol levels above 40-42.6 pg/mL are considered elevated and warrant clinical attention, particularly when accompanied by symptoms such as gynecomastia, sexual dysfunction, or breast tenderness 1
Estradiol >40 pg/mL with symptoms (gynecomastia, breast pain, nipple tenderness, or sexual dysfunction) requires intervention consideration 1
Estradiol >60 pg/mL regardless of symptoms warrants clinical monitoring and potential aromatase inhibitor therapy, especially in men on testosterone replacement 1
Target estradiol reduction is to <40 pg/mL while maintaining therapeutic testosterone levels (300-1000 ng/dL) in males on testosterone therapy 1

Elevated estradiol is expected due to peripheral aromatization of testosterone to estradiol in adipose tissue in males on testosterone therapy 1
Treatment decisions should incorporate symptomatology, not laboratory values in isolation, as breast symptoms may abate spontaneously with continued monitoring 1

Measure LH levels to assess hypothalamic-pituitary suppression when evaluating elevated estradiol in males 1
Assess for breast symptoms including gynecomastia, breast pain, and nipple tenderness when evaluating elevated estradiol in males 1

In transgender women on feminizing hormone therapy, the goal is to achieve estradiol and testosterone concentrations in the cisgender female reference range 2
Optimal estradiol doses for feminization are unclear, but most individuals achieve levels in the cisgender female reference range 2